The drug targets the overgrowth of synovial cells and inflammatory components that drive tumor development and joint ...

Deciphera Pharmaceuticals, LLC, a biopharmaceutical company focused on discovering, developing, and commercializing important ...

Romvimza, a drug for treating tenosynovial giant cell tumor, was initially developed by Deciphera Pharmaceuticals. Last year, Ono Pharmaceutical acquired Deciphera to build up its oncology ...

The Food and Drug Administration (FDA) has approved Romvimza ™ (vimseltinib) for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical ...

Vimseltinib improved objective response rate compared with placebo for patients with tenosynovial giant cell tumor, according to topline data from the agent’s manufacturer. Safety results from ...

About TGCT (PVNS/GCT-TS) TGCT, also referred to as pigmented villonodular synovitis (PVNS) or giant cell tumor of the tendon sheath (GCT-TS), is a rare, typically non-malignant tumor that can be ...

11544 Background: Tenosynovial giant cell tumor (TGCT) is a rare, locally aggressive tumor originating in the synovial lining of the joint, bursa, and tendon sheath. Since TGCT typically impacts ...

Secondary Source The Lancet Source Reference: Urakawa H, Imagama S "Vimseltinib for tenosynovial giant cell tumour" Lancet 2024; DOI: 10.1016/S0140-6736 (24)01113-9.

The U.S. Food and Drug Administration (FDA) has approved vimseltinib (RomvimzaTM) for adult patients with a rare condition called tenosynovial giant cell tumor (TGCT). TGCT is a tumor of the ...

The U.S. Food and Drug Administration has approved vimseltinib for adult patients with a rare condition called tenosynovial giant cell tumor, based on a trial led by an MSK researcher.

TURALIO® Final Long-Term Data Showed Sustained Clinical Benefit in Patients with Tenosynovial Giant Cell Tumor from Open-Label Extension of ENLIVEN Phase 3 Trial Final long-term efficacy and ...

Vimseltinib is the first and only therapy with a positive CHMP opinion for the treatment of TGCT in the European Union Deciphera Pharmaceuticals, LLC, a biopharmaceutical company focused on discoverin ...